Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Thanks for the presentation. So we saw really robust data from the PATHFNDR-1 study and now that we're on the cusp of PATHFNDR-2 data. Can you just recap the differences between the two trials and talk about the extent to which PATHFNDR-1 could support high likelihood of success for PATHFNDR-2?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Maybe we can spend a minute on the commercial potential for paltusotine specifically think about acromegaly. Is it possible to walk through a framework and how to think about that peak sales potential?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : You mentioned having better gross-to-nets you think than the injectables, where are the gross-to-nets for the injectable?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : So assuming PATHFNDR-2 is successful. What are some reasons why 100% of the patients on injectable therapy would not eventually adopt paltusotine?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : That's an interesting point about mobilizing patients since those physicians don't feel the pain of the shots. What are your kind of techniques or tactics you're going to use to do that?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : I think you talked about kind of the potential number of targeted prescribers. So how are you thinking about building a sales force in the US for acromegaly and what about outside the US? Do you want to go to independently or would you partner?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Are you switching to carcinoid? The initial data you provided look pretty clean consistent. So what is it that you want to see in the final data from that Phase 2 study?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : So speaking of Phase 3 planning, what is your initial thinking on the potential design or designs that you're kind of mulling over for a Phase 3 trial? And what specifically, what decisions around that will the Phase 2 data inform? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 09, 2024 / 11:45PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Can you talk about why you would or wouldn't think about expanding into broader NETs beyond personally?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Where should we think about pricing for paltusotine evolving if at all, if label does expand from acromegaly into carcinoid?

Question: Jess Fye - J.P. Morgan Securities LLC - Analyst : Okay. Looks like we're about out of time. So we'll stop there. Thank you.